IPSEN to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 16th, 2016

Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

PARIS, Nov. 10, 2016 /CNW/ -- Ipsen (Euronext: IPN; ADR: IPSEY) based in Boulogne-Billancourt, and focused on specialty pharmaceuticals in Oncology, Neurosciences and Endocrinology, today announced that VP of Investor Relations, Eugenia Litz, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on November 16, 2016.  This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.

DATE:   November 16^th, 2016
TIME:    11.00am ET
LINK:     www.adr.db.com/dbvic

This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Participation is free of charge.

It is recommended that investors pre-register to save time and receive event updates.

Recent Company Highlights

• August 01, 2016 – Ipsen reported that the U.S. Food and Drug Administration (FDA) approved Dysport^® (abobotulinumtoxinA) for injection for the treatment of pediatric lower limb (PLL) spasticity in children two years of age and older.
• September 14, 2016 – Ipsen disclosed that the European Commission approved Cabometyx™ (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
• October 7, 2016 – Ipsen announced that its partner Exelixis released Phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors.
• October 10, 2016 – Ipsen and its partner Exelixis announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

About Ipsen

Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditures neared €193 million. The Group has more than 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and are eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

SOURCE Ipsen

Eugenia Litz, Vice-President, Investor Relations, Tel.: [phone], E-mail: [email protected]; Côme de La Tour du Pin, Investor Relations Manager, Tel.: [phone], E-mail: [email protected], http://www.ipsen.com